share_log

Short Interest in Bionomics Limited (NASDAQ:BNOX) Rises By 150.0%

Short Interest in Bionomics Limited (NASDAQ:BNOX) Rises By 150.0%

Bionomics Limited(纳斯达克股票代码:BNOX)的空头利率上涨了150.0%
kopsource ·  2023/01/18 13:12

Bionomics Limited (NASDAQ:BNOX – Get Rating) was the recipient of a large growth in short interest during the month of December. As of December 30th, there was short interest totalling 1,000 shares, a growth of 150.0% from the December 15th total of 400 shares. Based on an average trading volume of 6,300 shares, the days-to-cover ratio is currently 0.2 days.

Bionomics Limited(纳斯达克股票代码:BNOX — Get Rating)是12月空头利率大幅增长的受益者。截至12月30日,空头利率共计1,000股,较12月15日的400股总额增长了150.0%。根据6,300股的平均交易量,目前的天数与覆盖率为0.2天。

Bionomics Stock Performance

生物学股票表现

Shares of BNOX stock traded down $0.22 during trading hours on Wednesday, reaching $4.13. 95 shares of the company's stock were exchanged, compared to its average volume of 3,657. The stock's 50 day moving average is $6.07 and its 200-day moving average is $7.02. Bionomics has a fifty-two week low of $3.51 and a fifty-two week high of $12.99.

周三交易时段,BNOX股票下跌0.22美元,至4.13美元。该公司股票共交易95股,而平均交易量为3,657股。该股的50天移动平均线为6.07美元,其200天移动平均线为7.02美元。Bionomics创下五十二周低点3.51美元,五十二周高点为12.99美元。

Get
获取
Bionomics
生物学
alerts:
警报:

Analysts Set New Price Targets

分析师设定了新的价格目标

BNOX has been the topic of a number of research reports. HC Wainwright lowered shares of Bionomics from a "buy" rating to a "neutral" rating in a research report on Monday, December 19th. Loop Capital assumed coverage on shares of Bionomics in a research note on Tuesday, November 1st. They issued a "buy" rating and a $23.00 price objective for the company. Finally, Evercore ISI restated an "in-line" rating and set a $6.00 price objective (down from $17.00) on shares of Bionomics in a research note on Tuesday, December 20th.

BNOX 一直是许多研究报告的主题。HC Wainwright在12月19日星期一的一份研究报告中将Bionomics的股票评级从 “买入” 下调至 “中性”。Loop Capital在11月1日星期二的一份研究报告中假设对Bionomics的股票进行了报道。他们为该公司发布了 “买入” 评级和23.00美元的目标价格。最后,Evercore ISI在12月20日星期二的一份研究报告中重申了 “同步” 评级,并为Bionomics的股票设定了6.00美元的价格目标(低于17.00美元)。

About Bionomics

关于生物经济学

(Get Rating)
(获取评分)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.

Bionomics Limited是一家临床阶段的生物制药公司,发现并开发了用于治疗中枢神经系统疾病和癌症的新型候选药物。该公司的主要候选药物包括 BNC210,这是a7烟碱乙酰胆碱受体的阴性变构调节剂,该药物正在治疗社交焦虑症的2期临床试验和治疗创伤后应激障碍的2b期临床试验中。

See Also

另见

  • Get a free copy of the StockNews.com research report on Bionomics (BNOX)
  • J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
  • Is Intel Stock On The Verge Of Breaking Out?
  • Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
  • Can Alaska Air Continue Soaring Above The Airline Industry?
  • Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
  • 免费获取 StockNews.com 生物学研究报告 (BNOX) 的副本
  • J.B. Hunt 持平,物流公司成为人们关注的焦点
  • 英特尔股票即将爆发吗?
  • 人们不对百事可乐的新苏打水 “满眼相看” 有关系吗?
  • 阿拉斯加航空能否继续飞越航空业?
  • 强生突围失败:收益能否提振股票?

Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.

接收《生物经济学日报》的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Bionomics及相关公司的最新新闻和分析师评级的简要每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发